SalaryGuide
AboutPricingFor Employers

Marketing jobs

23 marketing jobs

MSD logo
3 months ago

Associate Director, Global Marketing Engagement Influenza

MSD

Rahway, NJ (Hybrid)Full time$157K/yr – $247K/yr
MSD logo
4 months ago

Director Global Oncology Marketing Hematology

MSD

Rahway, NJ (Hybrid)Full time$191K/yr – $300K/yr
MSD logo
4 months ago

Associate Director, Marketing Operations, Strategy & Innovation

MSD

North Wales, PA (Hybrid)Full time$142K/yr – $224K/yr
Previous
12
Next

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

23 jobs
MSD logo

Associate Director, Global Marketing Engagement Influenza

MSD

Rahway, NJ (Hybrid)

$157K/yr - $247K/yrIn-houseFull-timeSenior level5+ years exp.
3 months ago
MSD logo

Director Global Oncology Marketing Hematology

MSD

Rahway, NJ (Hybrid)

$191K/yr - $300K/yrIn-houseFull-timeDirector/executive8+ years exp.
4 months ago
MSD logo

Associate Director, Marketing Operations, Strategy & Innovation

MSD

North Wales, PA (Hybrid)

$142K/yr - $224K/yrIn-houseFull-timeSenior level7+ years exp.
4 months ago
Previous12
MSD logo
MSD

Associate Director, Global Marketing Engagement Influenza

Rahway, NJ (Hybrid)

$157K/yr – $247K/yrSenior Level5+ years expFull time

Posted 3 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own analytics leadership for the Global influenza portfolio, guiding data-driven decisions and cross-functional collaboration to optimize launch and patient insights.

  • Own analytics for Global influenza portfolio, from data tools to patient insights.
  • Must-have: 5+ years in pharma analytics and insights.
  • Standout: cross-functional quarterback coordinating marketing, DHH, and pipeline teams.

Job Description

Responsibilities

  • Portfolio analytics: Lead development of commercial data and insights for Global influenza portfolio priorities. Conceptualize set of analytics capabilities and tools anchored to our marketing and launch frameworks to support decision making for Global influenza including patient insights, L3 early framework while focusing on our Company's experience.
  • Stakeholder Collaboration: Partner with global marketing teams, DHH teams, and other cross-functional teams to drive strategic decisions and increase commercial rigor through all phases of pipeline asset development. Serve as the Insights & Analytics quarterback to address key business questions through digital, data and analytics capabilities.
  • Strategy Enablement: Lead Strategic Portfolio Reviews, Trimester Business Reviews (QBRs), Prioritization meetings, etc. Synthesize & document key trade-off decisions and DHH aspirations for executive audiences via active updates to ongoing inventory of projects/initiatives (Book of Work).
  • Analytics Delivery: Proactively manage project(s) delivery with expertise in data manipulation, analysis, and visualization using tools such as Excel-VBA, PowerBI or similar technologies and capabilities. Leverage a variety of patient modeling techniques including statistical, patient-flow, and simulations-based techniques for insight generation.

Requirements

  • Bachelor's degree, preferably in a science or business-related field
  • 5+ years of relevant experience in insights & analytics, strategic planning, advanced analytics, market research, marketing or related roles within the pharmaceutical or biotechnology industry
  • Strong communication skills using effective storytelling grounded on data insights
  • Comfortable formulating actionable insights and recommendations from commercial analytics into presentations
  • Deep understanding of Real-world data assets and commercial healthcare data ecosystem
  • Experience conducting secondary data analytics on large datasets using relevant skills
  • Relationship-building, problem solving and influencing skills with an ability to collaborate cross-functionally
  • (Optional) Business Analysis, Business Decisions, Commercial Analytics, Data Science, Demand Management, Digital Analytics, Infectious Disease, Innovation, Insight Generation, Market Access, Marketing, Market Research, Patient Flow, Pharmacology, Problem Solving, Project Management, Requirements Management, Sourcing and Procurement, Stakeholder Relationship Management, Strategic Planning

Preferred

  • Advanced degree (e.g. MS, PharmD, PhD) preferred
  • Experience in healthcare datasets, insights, and analytics
  • Experience in Life Science or consulting industry
  • Deep knowledge and expertise in the Global Life Sciences Analytics space: US and Ex-US datasets, market research, forecasting, advanced analytics, predictive analytics, competitive intelligence, etc.
  • Vaccines and/or Infectious Disease experience

Benefits

  • We offer a comprehensive package of benefits. Available benefits include medical, dental, vision healthcare and other insurance benefits (for employee and family), retirement benefits, including 401(k), paid holidays, vacation, and compassionate and sick days.
MSD logo

MSD

4.1 Glassdoor

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Rahway, New Jersey, USA
41K employees (1,637 in marketing)
www.msd.com
85% recommend to a friend
90% CEO approval

Traffic Signals

Monthly Visitors
442.7K
Traffic Source Mix
Search
48.4%
Direct
32.9%
Referral
11%
Social
6.4%
Paid
1.2%

Headcount Trend

Current headcount: ~40.9K

Marketing Team

Marketing Team Size
1,404 (3% of company)
Median Career Experience
11 years
Median Tenure
7.3 years
Marketing Roles Posted (Last 30 Days)
30

People

Marketing Leadership

Urhan J.
Urhan J.
Associate Director, HPV Strategy & Product Development, HPV Global Marketing, Vaccines
At the company for 3 years 11 months
Alexandre A. Teixeira
Alexandre A. Teixeira
Regional Marketing Director Oncology
At the company for 5 years
Ritha Chandrachud
Ritha Chandrachud
AP Marketing Director; AP, China & Japan
At the company for 11 years 5 months

Recent News

MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
Sep 25, 2025 • Pharmaceutical Technology
Verona shareholders back $10bn MSD takeover
Sep 25, 2025 • pharmaphorum
BMS says it will set Cobenfy's UK price the same as the US
Sep 23, 2025 • pharmaphorum
FDA clears subcutaneous Keytruda in a boost to MSD
Sep 22, 2025 • pharmaphorum
Big Pharma’s pullback from the UK could have serious side-effects for Ireland
Sep 18, 2025 • Irish Times
UK ‘difficult’ operating environment says Merck boss after £1bn London site axed
Sep 16, 2025 • The Independent
AZ halts UK investment, and Lilly, Sanofi follow suit
Sep 14, 2025 • pharmaphorum
Reaction to MSD's UK exit as government tries to renew talks
Sep 12, 2025 • pharmaphorum
AstraZeneca pauses £200m Cambridge investment
Sep 12, 2025 • BBC
MSD calls off £1bn UK expansion amid government-big pharma tensions
Sep 11, 2025 • Pharmaceutical Technology
MSD calls off £1bn UK expansion amid government-big pharma tensions
Sep 11, 2025 • Yahoo Finance
Fresh blow to UK life sciences as MSD abandons £1bn project
Sep 11, 2025 • pharmaphorum
MSD, Ionis trumpet lipid-lowering drug data
Sep 3, 2025 • pharmaphorum
MSD’s oral PCSK9 scores Phase III hat-trick
Sep 2, 2025 • Clinical Trials Arena
MSD's oral cholesterol drug boosted by latest trial results
Sep 2, 2025 • Irish Examiner
MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial
Aug 28, 2025 • Clinical Trials Arena
GC Biopharma submits IND to begin Phase 3 Clinical Trial for BARYCELA in Thailand
Aug 28, 2025 • PR Newswire
Why most AI drug discovery startups struggle — and how Turbine plans to beat the odds
Aug 22, 2025 • Tech.eu
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
Aug 18, 2025 • BioSpace
Evaxion announces business update and second quarter 2025 financial results
Aug 15, 2025 • BioSpace
MSD reveals the first details of its job cut plans
Aug 14, 2025 • pharmaphorum
NICE backs KEYTRUDA combination for advanced endometrial cancer
Aug 7, 2025 • Pharma Times
After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line?
Aug 4, 2025 • KrASIA
MSD shares drop 5% amid plans for $3bn cost cutting strategy
Jul 29, 2025 • Pharmaceutical Technology
MSD trims outlook as it aims to shave $3bn off costs
Jul 29, 2025 • pharmaphorum
UK biotech investment "holding firm", says BIA
Jul 28, 2025 • pharmaphorum
MSD Commits to Veeva Vault CRM
Jul 21, 2025 • Veeva
Organon Expands Further with the Acquisition of MSD Biotech Site in the Netherlands
Jul 17, 2025 • NFIA
MSD progresses once-monthly HIV PrEP into Phase III
Jul 15, 2025 • Clinical Trials Arena
FDA to review MSD’s doravirine/islatravir NDA for HIV-1 treatment
Jul 14, 2025 • Pharmaceutical Technology
MSD acquisition to accelerate first-in-class COPD drug
Jul 10, 2025 • European Pharmaceutical Review
Epitopea Expands Clinical and Research Teams to Advance RNA-Based Immunotherapies
Jul 10, 2025 • PharmiWeb
Update: MSD confirms $10bn takeover deal for Verona Pharma
Jul 9, 2025 • pharmaphorum
There is a strong logic for US firms to continue making drugs in Ireland for non-US markets
Jul 7, 2025 • Irish Times
11 companies with research jobs you can apply to right now
Jul 3, 2025 • Silicon Republic
Belgian biotech stakeholders urge EU to fast-track innovation and financing reforms
Jul 1, 2025 • EURACTIV
Cancer Immunotherapy Surging with Checkpoint Inhibitors & CAR-T, Market to Reach $261B by 2033 | DataM Intelligence
Jun 23, 2025 • EIN Presswire
PhD student update from UCD Lyons calf research facility
Jun 22, 2025 • Agriland.ie
MSD and Daiichi announce first subject dosing in prostate cancer trial
Jun 19, 2025 • Clinical Trials Arena
Abbott, MSD partner to distribute oral anti-diabetic portfolio in India
Jun 19, 2025 • Hindu Business Line
FDA approves MSD’s Keytruda to treat head and neck cancer
Jun 16, 2025 • Pharmaceutical Technology
MSD begins Phase III trial of dengue vaccine
Jun 13, 2025 • Clinical Trials Arena
Pushback rises against RFK Jr's new ACIP membership
Jun 13, 2025 • pharmaphorum
MSD aims to plug dengue fever vaccine gap in US
Jun 12, 2025 • pharmaphorum
MSD’s Enflonsia receives FDA approval for RSV prophylaxis
Jun 11, 2025 • Clinical Trials Arena
MSD receives FDA approval for Enflonsia to prevent RSV
Jun 10, 2025 • Pharmaceutical Technology
MSD moves ahead in race to bring oral PCSK9 drug to market
Jun 10, 2025 • pharmaphorum
Beyfortus now has a direct rival after FDA OK for Enflonsia
Jun 10, 2025 • pharmaphorum
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results from Phase 1/2 Study of Kelun-Biotech's Trop2 Adc Sacituzumab Tirumotecan
Jun 10, 2025 • MarketScreener
Sanofi starts shipping RSV drug early as rival nears market
Jun 9, 2025 • pharmaphorum
Microbiotica appoints CIC's Robert Tansley as Chief Medical Officer
Jun 9, 2025 • businessweekly.co.uk
14 companies hiring in the automation space right now
Jun 6, 2025 • Silicon Republic
MSD rumoured to be eyeing $3bn+ MoonLake takeover
Jun 4, 2025 • pharmaphorum
ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I
Jun 2, 2025 • Clinical Trials Arena
I ditched my PC for the MSI Vector A18 HX A9W gaming laptop - here's my verdict after three weeks
May 31, 2025 • TechRadar.com
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
May 30, 2025 • Pharmaceutical Technology
ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
May 30, 2025 • Clinical Trials Arena
Vietnam Vaccine Market Outlook to 2029 | Government Reinforces Vaccine Production Capabilities with 20 Local Vaccine Types
May 30, 2025 • Research and Markets
Future of Work in Healthcare Strategic Intelligence Report 2025: Explore the Impacts of AI, Wearable Tech, and Automation Technologies
May 29, 2025 • Research and Markets
'Everything keeps going up' | Old infrastructure demands MSD price hike
May 28, 2025 • WHAS11
Biopharma Leaders Connect to Advance Development and Manufacturing at Veeva R&D and Quality Summit Europe
May 27, 2025 • PR Newswire UK
Best monitors of Computex 2025 - top ultra-wide, super-sized, and gaming screens on display
May 23, 2025 • TechRadar.com
New MSI Claw A8 AMD Handheld Games Console Unveiled
May 23, 2025 • Geeky Gadgets
Best gaming laptops of Computex 2025 - top picks from Asus, Acer, and more
May 22, 2025 • TechRadar.com
Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial
May 20, 2025 • Clinical Trials Arena
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
May 20, 2025 • PR Newswire
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer
May 16, 2025 • Clinical Trials Arena
FDA awards cancer drug approvals to AbbVie and MSD
May 15, 2025 • Pharmaceutical Technology
MSD adds new indication for Welireg in rare tumours
May 15, 2025 • pharmaphorum
MSI Raider 18 HX AI A2XW gaming laptop review
May 14, 2025 • PC Gamer
Techman Robot Showcases AI Cobot Innovations at Automate 2025
May 13, 2025 • PR Newswire
Novo Nordisk builds case for Norditropin successor
May 13, 2025 • pharmaphorum
Finnish startup Tilt Biotherapeutics moves closer to immune-oncology breakthrough with fresh €22.6 million
May 13, 2025 • EU-Startups
Global Health Leaders Converge in Abu Dhabi as IUHPE 2025 opens
May 13, 2025 • Zawya.com
19 exciting healthcare companies currently hiring
May 8, 2025 • Silicon Republic
Investing in Innovation Africa (i3) Selects 7 Startups for 3rd Cohort
May 6, 2025 • Techgist Africa | Africa Leading Tech News, Reviews and Tips
Gates Foundation-Backed Initiative Selects 7 African Health Startups for $225K Funding Each
May 5, 2025 • UrbanGeekz
MSI unveils its latest 4K QD-OLED gaming monitor
May 4, 2025 • KitGuru.net
Tecom Q1 revenue up 21% to $185mln
May 4, 2025 • Zawya.com
This MSI Raider gaming laptop costs more than my rent, but it’s worth every penny
May 2, 2025 • Laptop Mag
TECOM announces $185m revenues in Q1 2025
May 2, 2025 • Arabian Business
MSI Stealth 18 HX AI RTX 5090 Laptop : Redefining Power and Portability
May 2, 2025 • Geeky Gadgets
Pan-African e-health initiative i3 selects 7 startups for 3rd programme
May 2, 2025 • Disrupt Africa
TECOM Group’s Q1 2025 net profit rises by 23%
May 2, 2025 • Zawya.com
Construction begins on MSD’s $1bn biologics centre in Delaware, US
Apr 30, 2025 • Pharmaceutical Technology
Ekincare raises strategic investment from pharma giant MSD
Apr 29, 2025 • IndiaTimes
MSI Vector 16 HX AI gaming laptop review
Apr 29, 2025 • PC Gamer
MSD reports outcomes from Keytruda combination trial for head and neck cancer
Apr 28, 2025 • Clinical Trials Arena
Targeted Therapies for Non-Small Cell Lung Cancer (NSCLC): Addressing Ten Actionable Genomic Alterations in a Competitive Market
Apr 28, 2025 • Research and Markets
AbbVie makes its tariffs-driven investment play
Apr 28, 2025 • pharmaphorum
Amazon's huge Gaming Week sale is live: save up to $400 on gaming laptops
Apr 28, 2025 • TechRadar.com
MSD has gauged its financial hit from Trump tariffs
Apr 25, 2025 • pharmaphorum
PAHO and MSD for Mothers Launch Regional Project to Save Maternal Lives in Latin America
Apr 25, 2025 • Pan American Health Organization (PAHO)
Why the MSI Prestige A16 AI+ is the perfect productivity partner
Apr 25, 2025 • TechRadar.com
MSD’s Gardasil sales slide further due to China constraints
Apr 24, 2025 • Pharmaceutical Technology
MSI Z890 motherboards now support Intel 200S Boost technology
Apr 24, 2025 • KitGuru.net
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
Apr 24, 2025 • prnasia.com
Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025
Apr 24, 2025 • prnasia.com
Intel rolls out new 200S Boost technology
Apr 23, 2025 • KitGuru.net
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
Apr 23, 2025 • Morningstar.com